<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01172145</url>
  </required_header>
  <id_info>
    <org_study_id>1F32MH075583-01</org_study_id>
    <secondary_id>1F32MH075583-01</secondary_id>
    <nct_id>NCT01172145</nct_id>
  </id_info>
  <brief_title>Treatment of Apathy in Alzheimer's Disease With Modafinil</brief_title>
  <official_title>Treatment of Apathy in Alzheimer's Disease With Modafinil</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brown University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cephalon</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Brown University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study examined the effects of modafinil on apathetic symptomatology, performance of
      activities of daily living (ADLs) and caregiver burden in individuals with Alzheimer's
      disease (AD).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2005</start_date>
  <completion_date type="Actual">September 2007</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Apathy</measure>
    <time_frame>at baseline</time_frame>
    <description>The Frontal Systems Behavior Scale. Raw scores are converted to T-Scores using published norms. T-Scores have a mean of 50 and a standard deviation of 10. T-scores less than or equal to 64 are within average range. T-scores equal to or greater than 65 are indicative of a clinically significant problem. Higher scores indicate greater problem severity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apathy</measure>
    <time_frame>after 8 weeks of treatment</time_frame>
    <description>The Frontal Systems Behavior Scale.Raw scores are converted to T-Scores using published norms. T-Scores have a mean of 50 and a standard deviation of 10. T-scores less than or equal to 64 are within the average range. T-scores equal to or greater than 65 are indicative of a clinically significant problem. Higher scores indicate greater problem severity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lawton Brody Activities of Daily Living Questionnaire</measure>
    <time_frame>at baseline</time_frame>
    <description>Caregiver reported performance of personal and instrumental activities of daily living (ADLs. There are 6 personal ADLs (i.e. dressing, grooming, eating, etc) and 8 instrumental ADLs (i.e. managing finances, transportation, food preparation) which are assessed. Each item is awarded 2 points for fully independent, 1 point for minimal or moderate support required, and 0 points for full support. Maximum score for independence with all personal and instrumental ADL's is 28.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Direct Assessment of Functional Status Scale</measure>
    <time_frame>at baseline</time_frame>
    <description>A direct, examiner observed assessment of basic and instrumental activities of daily living. Participants are awarded points for correct performance of activities. Raw score is used for statistical comparison.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Zarit Burden Inventory</measure>
    <time_frame>at baseline</time_frame>
    <description>Measure of Caregiver Burden. Caregiver rates each item assessing burden on a 0 to 4 point scale with higher numbers reflecting more frequent occurence of the behavior or feeling being assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lawton Brody Activities of Daily Living Questionnaire</measure>
    <time_frame>after 8 weeks of treatment</time_frame>
    <description>Caregiver reported performance of personal and instrumental activities of daily living (ADLs. There are 6 personal ADLs (i.e. dressing, grooming, eating, etc) and 8 instrumental ADLs (i.e. managing finances, transportation, food preparation) which are assessed. Each item is awarded 2 points for fully independent, 1 point for minimal or moderate support required, and 0 points for full support. Maximum score for independence with all personal and instrumental ADL's is 28.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Direct Assessment of Functional Status Scale</measure>
    <time_frame>after 8 weeks of treatment</time_frame>
    <description>A direct, examiner observed assessment of basic and instrumental activities of daily living. Participants are awarded points for correct performance of activities. Raw score is used for statistical comparison.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Zarit Burden Inventory</measure>
    <time_frame>after 8 weeks of treatment</time_frame>
    <description>Measure of Caregiver Burden. Caregiver rates each item assessing burden on a 0 to 4 point scale with higher numbers reflecting more frequent occurence of the behavior or feeling being assessed.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Apathy</condition>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>Cholinesterase inhibitor only</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cholinesterase Plus Modafinil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Modafinil</intervention_name>
    <description>100 mg in the morning for the first week and 200 mg in the morning for the remaining seven weeks</description>
    <arm_group_label>Cholinesterase Plus Modafinil</arm_group_label>
    <other_name>Provigil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>100 mg in the morning for the first week and 200 mg in the morning for the remaining seven weeks</description>
    <arm_group_label>Cholinesterase inhibitor only</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosis of mild to moderate stage Probable Alzheimer's disease

          -  on a stable dose of a cholinesterase inhibitor medication for at least 30 days

          -  clinically elevated levels of apathy as measured by the Frontal Systems Behavior Scale

        Exclusion Criteria:

          -  diagnosis of Major Depression

          -  focal brain lesion on neuroimaging

          -  history of significant substance abuse

          -  history of significant head trauma with loss if consciousness &gt;10 minutes
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laura L Frakey, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Hospital of Rhode Island</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Butler Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02906</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 28, 2010</study_first_submitted>
  <study_first_submitted_qc>July 28, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2010</study_first_posted>
  <results_first_submitted>August 4, 2010</results_first_submitted>
  <results_first_submitted_qc>February 9, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 4, 2011</results_first_posted>
  <last_update_submitted>February 9, 2011</last_update_submitted>
  <last_update_submitted_qc>February 9, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 4, 2011</last_update_posted>
  <responsible_party>
    <name_title>Laura L. Frakey</name_title>
    <organization>Brown University</organization>
  </responsible_party>
  <keyword>apathy</keyword>
  <keyword>Alzheimer's disease</keyword>
  <keyword>activities of daily living performance</keyword>
  <keyword>caregiver burden</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Modafinil</mesh_term>
    <mesh_term>Armodafinil</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited from a Memory Disorders Clinic and the community between 2005 and 2007</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Cholinesterase Inhibitor Only</title>
          <description>participants who received placebo</description>
        </group>
        <group group_id="P2">
          <title>Cholinesterase Plus Modafinil</title>
          <description>participants who received modafinil (200 mg per day)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cholinesterase Inhibitor Only</title>
          <description>participants who received placebo</description>
        </group>
        <group group_id="B2">
          <title>Cholinesterase Plus Modafinil</title>
          <description>participants who received modafinil (200 mg per day)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="22"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79.36" spread="7.62"/>
                    <measurement group_id="B2" value="75.27" spread="8.34"/>
                    <measurement group_id="B3" value="77.32" spread="8.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Apathy</title>
        <description>The Frontal Systems Behavior Scale. Raw scores are converted to T-Scores using published norms. T-Scores have a mean of 50 and a standard deviation of 10. T-scores less than or equal to 64 are within average range. T-scores equal to or greater than 65 are indicative of a clinically significant problem. Higher scores indicate greater problem severity.</description>
        <time_frame>at baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cholinesterase Inhibitor Only</title>
            <description>participants who received placebo</description>
          </group>
          <group group_id="O2">
            <title>Cholinesterase Plus Modafinil</title>
            <description>participants who received modafinil (200 mg per day)</description>
          </group>
        </group_list>
        <measure>
          <title>Apathy</title>
          <description>The Frontal Systems Behavior Scale. Raw scores are converted to T-Scores using published norms. T-Scores have a mean of 50 and a standard deviation of 10. T-scores less than or equal to 64 are within average range. T-scores equal to or greater than 65 are indicative of a clinically significant problem. Higher scores indicate greater problem severity.</description>
          <units>T-score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.91" spread="11.95"/>
                    <measurement group_id="O2" value="95.64" spread="10.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.181</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.385</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.86</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16.86</ci_lower_limit>
            <ci_upper_limit>3.40</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Apathy</title>
        <description>The Frontal Systems Behavior Scale.Raw scores are converted to T-Scores using published norms. T-Scores have a mean of 50 and a standard deviation of 10. T-scores less than or equal to 64 are within the average range. T-scores equal to or greater than 65 are indicative of a clinically significant problem. Higher scores indicate greater problem severity.</description>
        <time_frame>after 8 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cholinesterase Inhibitor Only</title>
            <description>participants who received placebo</description>
          </group>
          <group group_id="O2">
            <title>Cholinesterase Plus Modafinil</title>
            <description>participants who received modafinil (200 mg per day)</description>
          </group>
        </group_list>
        <measure>
          <title>Apathy</title>
          <description>The Frontal Systems Behavior Scale.Raw scores are converted to T-Scores using published norms. T-Scores have a mean of 50 and a standard deviation of 10. T-scores less than or equal to 64 are within the average range. T-scores equal to or greater than 65 are indicative of a clinically significant problem. Higher scores indicate greater problem severity.</description>
          <units>T-score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.09" spread="13.52"/>
                    <measurement group_id="O2" value="89.09" spread="9.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lawton Brody Activities of Daily Living Questionnaire</title>
        <description>Caregiver reported performance of personal and instrumental activities of daily living (ADLs. There are 6 personal ADLs (i.e. dressing, grooming, eating, etc) and 8 instrumental ADLs (i.e. managing finances, transportation, food preparation) which are assessed. Each item is awarded 2 points for fully independent, 1 point for minimal or moderate support required, and 0 points for full support. Maximum score for independence with all personal and instrumental ADL's is 28.</description>
        <time_frame>at baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cholinesterase Inhibitor Only</title>
            <description>participants who received placebo</description>
          </group>
          <group group_id="O2">
            <title>Cholinesterase Plus Modafinil</title>
            <description>participants who received modafinil (200 mg per day)</description>
          </group>
        </group_list>
        <measure>
          <title>Lawton Brody Activities of Daily Living Questionnaire</title>
          <description>Caregiver reported performance of personal and instrumental activities of daily living (ADLs. There are 6 personal ADLs (i.e. dressing, grooming, eating, etc) and 8 instrumental ADLs (i.e. managing finances, transportation, food preparation) which are assessed. Each item is awarded 2 points for fully independent, 1 point for minimal or moderate support required, and 0 points for full support. Maximum score for independence with all personal and instrumental ADL's is 28.</description>
          <units>raw score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.00" spread="5.25"/>
                    <measurement group_id="O2" value="16.18" spread="4.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Direct Assessment of Functional Status Scale</title>
        <description>A direct, examiner observed assessment of basic and instrumental activities of daily living. Participants are awarded points for correct performance of activities. Raw score is used for statistical comparison.</description>
        <time_frame>at baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cholinesterase Inhibitor Only</title>
            <description>participants who received placebo</description>
          </group>
          <group group_id="O2">
            <title>Cholinesterase Plus Modafinil</title>
            <description>participants who received modafinil (200 mg per day)</description>
          </group>
        </group_list>
        <measure>
          <title>The Direct Assessment of Functional Status Scale</title>
          <description>A direct, examiner observed assessment of basic and instrumental activities of daily living. Participants are awarded points for correct performance of activities. Raw score is used for statistical comparison.</description>
          <units>raw score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.09" spread="7.84"/>
                    <measurement group_id="O2" value="84.55" spread="16.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Zarit Burden Inventory</title>
        <description>Measure of Caregiver Burden. Caregiver rates each item assessing burden on a 0 to 4 point scale with higher numbers reflecting more frequent occurence of the behavior or feeling being assessed.</description>
        <time_frame>at baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cholinesterase Inhibitor Only</title>
            <description>participants who received placebo</description>
          </group>
          <group group_id="O2">
            <title>Cholinesterase Plus Modafinil</title>
            <description>participants who received modafinil (200 mg per day)</description>
          </group>
        </group_list>
        <measure>
          <title>Zarit Burden Inventory</title>
          <description>Measure of Caregiver Burden. Caregiver rates each item assessing burden on a 0 to 4 point scale with higher numbers reflecting more frequent occurence of the behavior or feeling being assessed.</description>
          <units>raw score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.36" spread="21.09"/>
                    <measurement group_id="O2" value="31.18" spread="8.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lawton Brody Activities of Daily Living Questionnaire</title>
        <description>Caregiver reported performance of personal and instrumental activities of daily living (ADLs. There are 6 personal ADLs (i.e. dressing, grooming, eating, etc) and 8 instrumental ADLs (i.e. managing finances, transportation, food preparation) which are assessed. Each item is awarded 2 points for fully independent, 1 point for minimal or moderate support required, and 0 points for full support. Maximum score for independence with all personal and instrumental ADL's is 28.</description>
        <time_frame>after 8 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cholinesterase Inhibitor Only</title>
            <description>participants who received placebo</description>
          </group>
          <group group_id="O2">
            <title>Cholinesterase Plus Modafinil</title>
            <description>participants who received modafinil (200 mg per day)</description>
          </group>
        </group_list>
        <measure>
          <title>Lawton Brody Activities of Daily Living Questionnaire</title>
          <description>Caregiver reported performance of personal and instrumental activities of daily living (ADLs. There are 6 personal ADLs (i.e. dressing, grooming, eating, etc) and 8 instrumental ADLs (i.e. managing finances, transportation, food preparation) which are assessed. Each item is awarded 2 points for fully independent, 1 point for minimal or moderate support required, and 0 points for full support. Maximum score for independence with all personal and instrumental ADL's is 28.</description>
          <units>raw score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.00" spread="5.54"/>
                    <measurement group_id="O2" value="15.64" spread="5.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Direct Assessment of Functional Status Scale</title>
        <description>A direct, examiner observed assessment of basic and instrumental activities of daily living. Participants are awarded points for correct performance of activities. Raw score is used for statistical comparison.</description>
        <time_frame>after 8 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cholinesterase Inhibitor Only</title>
            <description>participants who received placebo</description>
          </group>
          <group group_id="O2">
            <title>Cholinesterase Plus Modafinil</title>
            <description>participants who received modafinil (200 mg per day)</description>
          </group>
        </group_list>
        <measure>
          <title>The Direct Assessment of Functional Status Scale</title>
          <description>A direct, examiner observed assessment of basic and instrumental activities of daily living. Participants are awarded points for correct performance of activities. Raw score is used for statistical comparison.</description>
          <units>raw score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.36" spread="8.35"/>
                    <measurement group_id="O2" value="85.27" spread="14.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Zarit Burden Inventory</title>
        <description>Measure of Caregiver Burden. Caregiver rates each item assessing burden on a 0 to 4 point scale with higher numbers reflecting more frequent occurence of the behavior or feeling being assessed.</description>
        <time_frame>after 8 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cholinesterase Inhibitor Only</title>
            <description>participants who received placebo</description>
          </group>
          <group group_id="O2">
            <title>Cholinesterase Plus Modafinil</title>
            <description>participants who received modafinil (200 mg per day)</description>
          </group>
        </group_list>
        <measure>
          <title>Zarit Burden Inventory</title>
          <description>Measure of Caregiver Burden. Caregiver rates each item assessing burden on a 0 to 4 point scale with higher numbers reflecting more frequent occurence of the behavior or feeling being assessed.</description>
          <units>raw score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.00" spread="20.56"/>
                    <measurement group_id="O2" value="30.00" spread="4.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Cholinesterase Inhibitor Only</title>
          <description>participants who received placebo</description>
        </group>
        <group group_id="E2">
          <title>Cholinesterase Plus Modafinil</title>
          <description>participants who received modafinil (200 mg per day)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Motor Tics</sub_title>
                <description>assessed by study neurologist</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Laura L. Frakey</name_or_title>
      <organization>Brown University</organization>
      <phone>401-729-3163</phone>
      <email>lfrakey@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

